State-owned enterprises resource advantages to the raw material drug operation pile

with the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk of raw materials domestic demand is also declining, internal and external problems are testing the production of raw materialsFor these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategy4cT
As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprisesShen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical developmentChina's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary peopleState-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry4cT
The traditional bulk API developed in China is dominated by penicillin series, vitamin series and anti-hot analgesicsWith the transfer of the global API industry in the 1990s, China has gradually become the traditional bulk API production center4cT
Public data show that in 1999 China's EXPORT volume of API intermediates was 520.8 million tons, amounting to 2,047 million U.Sdollars, while in 2004 the export volume has soared to 10.436 million tons, amounting to 3.756 billion U.Sdollars, and the average growth rate of API exports in the past six years has reached more than 17%Among them, penicillin and vitamin C accounted for more than 50% of the world supply4cT
"The field of penicillin industrial salt had six price wars before 2006, each time blood-soaked: who has a large tonnage, low cost, who can carry it, and vice versa, is squeezed out of the marketOne industry insider recalledThrough the price war, penicillin and other bulk raw materials and other pharmaceutical production capacity continues to be concentrated, leading enterprises have further consolidated the position4cT
Aoxing pharmaceutical government consultant, API industry veteran Xu Weifeng believes that it is the unique resource advantages of state-owned enterprises caused by large enterprise disease, the formation of piles of raw materials management situation4cT
Over the years, China to scale, production capacity, gross output value and other indicators to assess the industry ranking, the implementation of export-oriented policy, long-term neglect of profits and the core competitiveness of enterprises is one of the reasons that lead enterprises to chase blindly biggerAfter China's accession to the WTO, the scale benefit in seeking comparative advantage is also one of the promoters of the blind expansion of production4cTwith the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk apibdemand demand is also declining, internal and external problems are testing the production of raw materialsFor these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategy 4cT
　　As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprises Shen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical development China's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary people State-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry 4cT
　　The traditional bulk API developed in China is dominated by penicillin series, vitamin series and anti-hot analgesics With the transfer of the global API industry in the 1990s, China has gradually become the traditional bulk API production center 4cT
　　Public data show that in 1999 China's EXPORT volume of API intermediates was 520.8 million tons, amounting to 2,047 million U.S dollars, while in 2004 the export volume has soared to 10.436 million tons, amounting to 3.756 billion U.S dollars, and the average growth rate of API exports in the past six years has reached more than 17% Among them, penicillin and vitamin C accounted for more than 50% of the world supply 4cT
　　"The field of penicillin industrial salt had six price wars before 2006, each time blood-soaked: who has a large tonnage, low cost, who can carry it, and vice versa, is squeezed out of the market One industry insider recalled Through the price war, penicillin and other bulk raw materials and other pharmaceutical production capacity continues to be concentrated, leading enterprises have further consolidated the position 4cT
　　Aoxing pharmaceutical government consultant, API industry veteran Xu Weifeng believes that it is the unique resource advantages of state-owned enterprises caused by large enterprise disease, the formation of piles of raw materials management situation 4cT
　　Over the years, China to scale, production capacity, gross output value and other indicators to assess the industry ranking, the implementation of export-oriented policy, long-term neglect of profits and the core competitiveness of enterprises is one of the reasons that lead enterprises to chase blindly bigger After China's accession to the WTO, the scale benefit in seeking comparative advantage is also one of the promoters of the blind expansion of production 4cT